annual meeting program - American Society of Clinical Oncology

SUNDAY
Sunday, June 6, 2010
Brd. 36C Association of gender and passive smoking with epidermal growth factor
receptor mutations in never-smokers with non-small cell lung cancer: A
prospective study based on detailed passive smoking questionnaire.
(Abstract #7558)
T. Kawaguchi, M. Ando, A. Kubo, M. Takada, S. Atagi, K. Okishio, K. Asami,
A. Matsumura, K. Tsujino, H. Sasaki
Brd. 36D A phase II study of gefitinib versus vinorelbine or gemcitabine in
chemotherapy-naïve elderly patients with advanced non-small cell lung
cancer based on epidermal growth factor receptor mutation status.
(Abstract #7559)
S. Fujita, N. Katakami, K. Masago, H. Yoshioka, K. Tomii, T. Kaneda,
M. Hirabayashi, T. Morizane, T. Mio
Brd. 36E Assessment of epidermal growth factor receptor (EGFR) and K-ras mutation
status in cytologic stained smears of non-small cell lung cancer (NSCLC)
patients. (Abstract #7560)
M. D. Lozano, A. Gurpide, J. I. Echeveste, A. Del Barrio, J. L. Perez-Gracia,
L. M. Seijo, J. Zulueta, J. M. López-Picazo, I. Gil-Bazo, S. Martin-Algarra
Brd. 36F First-line gefitinib therapy for elder advanced non-small cell lung cancer
patients with epidermal growth factor receptor mutations: Multicenter phase
II trial (NEJ 003 study). (Abstract #7561)
Y. Minegishi, M. Maemondo, S. Okinaga, N. Morikawa, A. Inoue, K. Kobayashi,
M. Harada, K. Hagiwara, T. Nukiwa, A. Gemma
Brd. 36G Optimization of patient selection for EGFR-TKIs in advanced non-small cell
lung cancer by combined analysis of MET, EGFR, KRAS, and PIK3CA
mutations. (Abstract #7562)
V. Ludovini, F. Bianconi, L. Pistola, R. Chiari, F. R. Tofanetti, A. Siggillino,
E. Baldelli, R. Colella, M. G. Mameli, L. Crinò
Brd. 36H Predictive value of serum HGF for treatment response to EGFR tyrosine
kinase inhibitor in patients with lung adenocarcinoma. (Abstract #7563)
K. Kasahara, T. Arao, K. Sakai, A. Sakai, T. Sone, M. Nishio, T. Ohira, N. Ikeda,
T. Yamanaka, K. Nishio
Brd. 37A Effect of tumor-specific KRAS mutational status on impact of anti-EGFR
therapy in non-small cell lung cancer (NSCLC). (Abstract #7564)
M. C. Garassino, M. Marabese, M. Broggini, C. Lauricella, I. Floriani, O. Martelli,
S. Marsoni, G. Gherardi, G. Farina, A. Scanni, TAILOR Study Group
Brd. 37B Erlotinib versus carboplatin/vinorelbine in elderly patients (age 70 or older)
with advanced non-small cell lung carcinoma (NSCLC): A randomized phase
II study of the German Thoracic Oncology Working Group. (Abstract #7565)
M. Reck, J. Von Pawel, J. R. Fischer, C. Kortsik, S. Bohnet, M. von Eiff,
W. Koester, M. Thomas, P. Schnabel, K. M. Deppermann, German Thoracic
Oncology Working Group
Brd. 37C Comparison of adverse events of erlotinib with those of gefitinib in Japanese
patients with NSCLC. (Abstract #7566)
T. Suzumura, S. Kudoh, T. Kimura, K. Umekawa, H. Tanaka, S. Mitsuoka,
N. Yoshimura, K. Hirata
Brd. 37D Changes in FDG- and FLT-PET imaging in patients with non-small cell lung
cancer (NSCLC) following treatment with erlotinib (E). (Abstract #7567)
L. R. Mileshkin, B. G. Hughes, P. Mitchell, V. Charu, B. J. Gitlitz, D. Macfarlane,
W. Yu, A. Pirzkall, R. Hicks, B. M. Fine
Brd. 37E Plans of American medical oncologists (AMO) to order molecular testing
before starting first-line therapy for patients with stage IV non-small cell lung
cancer (NSCLC). (Abstract #7568)
M. R. Green, A. J. Wozniak, J. Willey, K. E. Lemke, H. J. West
Brd. 37F Phase II randomized study of the safety, efficacy, metabolism, and molecular
targets of erlotinib in African Americans (AA) with NSCLC. (Abstract #7569)
M. A. Villalona-Calero, T. Stinchcombe, M. A. Phelps, S. L. Starrett, A. C. Papp,
A. M. Ghany, W. J. Hicks, G. A. Otterson, M. A. Socinski, W. Zhao
216